Leading psychedelics company developing and deploying psychedelics-inspired medicines to improve mental wellness MindMed Inc. (MNMD) (NEO: MMED) announced having been granted approval to commence its phase 1 clinical trial evaluating the acute effects of mescaline.
MindMed secured this approval from local Swiss ethics committee allowing the company to conduct phase 1 clinical trial which will evaluate the effects of different doses of mescaline and the role of the serotonin 5-HT2A receptor in mescaline-induced altered states of consciousness (MDR-Study).
MindMed is looking forward to begin this phase clinical trial at University Hospital Basel’s Liechti Lab before the month is over. Dr. Matthias Liechti, a professor for clinical pharmacology and internal medicine at the University Hospital Basel says this will be the first ever research of such kind.
“This study will, we believe, provide the first modern research data on mescaline regarding dosing and mechanism of action in humans,” said Dr. Liechti.
Mescaline is a classic serotonergic hallucinogen with long non-regulated history of spiritual use which can be compared to LSD psilocybin.
“Mescaline is an archetypical psychedelic with surprisingly little contemporary scientific information on its pharmacology and effects in humans,” added Dr. Liechti.
